Peptide Safety — Complete Reference

Complete Peptide Safety Reference

Comprehensive safety profiles for all FDA-approved and major investigational peptides.

Safety Classification

Category	Description
Contraindication	Condition under which peptide must not be used
Warning	Condition requiring special precautions
Precaution	Condition requiring monitoring or dose adjustment
Adverse effect	Undesirable effect occurring during treatment

Severity Grading

Grade	Severity	Management
1	Mild	Monitor
2	Moderate	Dose adjustment or symptomatic treatment
3	Severe	Hospitalization or discontinuation
4	Life-threatening	Emergency intervention

---

GLP-1 Receptor Agonists

Semaglutide (Ozempic/Mounjaro)

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Hypersensitivity to semaglutide

Warnings:

• Risk of thyroid C-cell tumors (rodent studies)
• Acute pancreatitis (rare)
• Acute gallbladder disease
• Hypoglycemia (with insulin/SU)
• Acute kidney injury (dehydration from nausea/vomiting)
• Diabetic retinopathy complications
• Increased heart rate

Common adverse effects (≥5%):

• Nausea (15–20%)
• Diarrhea (10–15%)
• Vomiting (10–15%)
• Abdominal pain (10–15%)
• Constipation (5–10%)
• Injection site reactions (5–10%)
• Headache (5–10%)
• Fatigue (5–10%)

Serious adverse effects:

• Pancreatitis (<1%)
• Gallbladder disease (<1%)
• Severe GI events (ileus, obstruction)
• Anaphylaxis (very rare)
• Angioedema (very rare)

Monitoring:

• Thyroid examination (annual)
• Pancreatic enzymes (if symptoms)
• Renal function (baseline, periodic)
• Diabetic retinopathy status (annual)

Tirzepatide (Mounjaro/Zepbound)

Contraindications:

• Personal or family history of MTC
• MEN 2
• Hypersensitivity to tirzepatide

Warnings:

• Same as semaglutide (thyroid C-cell tumors, pancreatitis, gallbladder disease)
• Hypoglycemia risk with insulin/SU

Common adverse effects (≥5%):

• Nausea (15–25%)
• Diarrhea (15–20%)
• Decreased appetite (10–15%)
• Vomiting (5–10%)
• Constipation (5–10%)
• Injection site reactions (5–10%)
• Dyspepsia (5–10%)

Serious adverse effects: Same as semaglutide

Liraglutide (Victoza/Saxenda)

Contraindications: Same as semaglutide

Warnings: Same as semaglutide

Additional adverse effects:

• Discontinuation due to GI effects (10–15%)
• Injection site reactions (10–20%)

---

Amylin Analogues

Pramlintide (Symlin)

Contraindications:

• Hypersensitivity to pramlintide
• gastroparesis
• HbA1c >9%

Warnings:

• Severe hypoglycemia (especially with insulin)
• Delayed gastric emptying

Common adverse effects:

• Nausea (15–25%)
• Headache (10–15%)
• Injection site reactions (10–15%)
• Abdominal pain (5–10%)

Monitoring:

• Blood glucose closely
• Insulin dose reduction (50% bolus)

---

Insulin Analogues

All Insulin Analogsues

Contraindications:

• Hypoglycemia
• Hypersensitivity

Warnings:

• Hypoglycemia (most common serious adverse effect)
• Hypokalemia
• Weight gain
• Lipodystrophy
• Anaphylaxis (rare)

Common adverse effects:

• Hypoglycemia (10–30%)
• Weight gain (1–5 kg)
• Injection site reactions (5–10%)
• Lipodystrophy (rare)
• Edema (1–5%)

Technosphere Insulin (Afrezza)

Contraindications:

• Chronic lung disease (asthma, COPD)
• FEV1 <70% predicted
• Current smoking or recently quit (<6 months)
• DKA
• Hypersensitivity to fumaryl diketopiperazine
• Children <18 years

Warnings:

• Acute bronchospasm (1–3%)
• FEV1 decline (30–50 mL)
• Cough (30–50%)
• Throat irritation

Monitoring:

• FEV1 at baseline, 3 months, 6 months, then annually
• Lung function stability

---

Growth Hormone Secretagogues

CJC-1295 DAC (Investigational)

Contraindications:

• Active cancer
• Diabetic retinopathy
• Obesity with OSA (relative)
• Hypothyroidism (untreated)

Warnings:

• Insulin resistance
• Water retention
• Gynecomastia (rare)
• IGF-1 elevation

Common adverse effects:

• Injection site reactions (10–20%)
• Water retention (5–10%)
• Joint pain (5–10%)
• Headache (5–10%)
• Fatigue (5–10%)

Monitoring:

• Fasting glucose (baseline, q3 months)
• IGF-1 levels (q3 months)
• HOMA-IR (baseline, q6 months)

Ipamorelin (Investigational)

Contraindications: Same as CJC-1295

Warnings: Similar to CJC-1295 (less severe)

Common adverse effects:

• Injection site reactions (5–10%)
• Headache (5–10%)
• Flushing (5–10%)

GHRP-6 (Investigational)

Contraindications: Same as CJC-1295

Warnings:

• Increased appetite (80–90%)
• Cortisol elevation
• Prolactin increase

Common adverse effects:

• Hunger pangs (50–70%)
• Flushing (20–30%)
• Dizziness (10–15%)
• GI discomfort (5–10%)

MK-677 (Investigational)

Contraindications: Same as CJC-1295

Warnings:

• Insulin resistance (significant)
• Cortisol elevation (20–30%)
• Water retention
• Gynecomastia (5–10%)

Common adverse effects:

• Increased appetite (30–50%)
• Water retention (10–20%)
• Joint pain (5–10%)
• Muscle cramps (5–10%)

---

Melanocortin Analogues

Melanotan II (Research Chemical)

Contraindications:

• History of melanoma
• Cardiovascular disease
• Hypertension
• Pregnancy

Warnings:

• Cardiovascular effects (BP, HR changes)
• Hyperpigmentation
• Nausea
• Theoretical melanoma risk (unresolved)

Common adverse effects:

• Nausea (30–50%)
• Flushing (20–30%)
• Blood pressure changes (20–40%)
• Hyperpigmentation (80–100%)
• Appetite suppression (20–30%)

Bremelanotide (Vyleesi)

Contraindications:

• Hypertension
• Cardiovascular disease
• Pregnancy
• Hypersensitivity

Warnings:

• Blood pressure elevation
• Nausea
• Hyperpigmentation

Common adverse effects:

• Nausea (40%)
• Flushing (20%)
• Headache (13%)
• Injection site reactions (10%)
• Hyperpigmentation (10%)

Afamelanotide (Scenesse)

Contraindications:

• Hypersensitivity to afamelanotide

Warnings:

• Photosensitivity
• Liver function monitoring

Common adverse effects:

• Headache (20–30%)
• Nausea (10–20%)
• Injection site reactions (10–15%)
• Fatigue (5–10%)

---

Repair Peptides (Research Chemicals)

BPC-157

Contraindications:

• No known contraindications
• Not recommended in active malignancy (theoretical)

Warnings:

• Limited human safety data
• Unknown long-term effects

Common adverse effects:

• Very few reported
• Injection site reactions (rare)
• GI discomfort (rare)

Thymosin Beta-4 / TB-500

Contraindications:

• Active malignancy (theoretical concern)
• Pregnancy (no data)

Warnings:

• Limited human safety data
• Unknown long-term effects

Common adverse effects:

• Injection site reactions (5–10%)
• Headache (rare)
• Fatigue (rare)

GHK-Cu

Contraindications:

• Hypersensitivity to copper

Warnings:

• Copper toxicity risk (high doses)
• Limited systemic data

Common adverse effects:

• Injection site reactions (rare)
• Skin irritation (topical)

---

Somatostatin Analogues

Octreotide (Sandostatin)

Contraindications:

• Hypersensitivity to octreotide

Warnings:

• Gallbladder disease (30%)
• Hyperglycemia
• Hypothyroidism
• Bradycardia
• Vitamin B12 deficiency (long-term)

Common adverse effects:

• GI symptoms (30–40%)
• Gallstones (15–30%)
• Injection site reactions (10–20%)
• Hyperglycemia (10–20%)
• Hypothyroidism (5–10%)

Monitoring:

• Thyroid function (annual)
• Vitamin B12 (annual)
• Gallbladder ultrasound (symptoms)
• Glucose (periodic)

Lanreotide (Somatuline)

Same safety profile as octreotide

Pasireotide (Signifor)

Contraindications: Same as octreotide

Warnings:

• Hyperglycemia (severe, 40–70%)
• Diabetes (20–30%)
• QT prolongation

Monitoring:

• Glucose (frequent)
• HbA1c (monthly)
• ECG (baseline)

---

Thymic Peptides

Thymosin Alpha-1

Contraindications:

• Hypersensitivity to thymosin alpha-1
• Immunosuppressant therapy (relative)

Warnings:

• Limited human safety data
• Theoretical risk of autoimmunity

Common adverse effects:

• Injection site reactions (5–10%)
• Fever (2–5%)
• Fatigue (2–3%)

---

Neuropeptides

Oxytocin

Contraindications:

• Hypersensitivity to oxytocin
• Active labor with cephalopelvic disproportion
• Vaginal delivery with previous cesarean
• Uterine hypertonicity

Warnings:

• Water intoxication (hyponatremia)
• Hypertension (with ergot alkaloids)
• Uterine tachysystole
• Fetal distress

Common adverse effects:

• Nausea (10–20%)
• Vomiting (5–10%)
• Uterine tachysystole (5–10%)
• Water intoxication (rare)

Desmopressin (DDAVP)

Contraindications:

• Hyponatremia
• Heart failure
• Polydipsia
• Hypersensitivity

Warnings:

• Water intoxication
• Hyponatremia
• Seizures (with severe hyponatremia)

Common adverse effects:

• Headache (10–15%)
• Nausea (5–10%)
• Abdominal pain (5–10%)
• Hyponatremia (5–10%)

Monitoring:

• Serum sodium (baseline, periodic)
• Fluid balance

---

Natriuretic Peptides

Nesiritide (Natrecor)

Contraindications:

• Hypotension (SBP <90 mmHg)
• Constrictive pericarditis
• Restrictive cardiomyopathy
• Cardiac tamponade
• Aortic stenosis

Warnings:

• Hypotension (35%)
• Renal impairment

Common adverse effects:

• Hypotension (35%)
• Nausea (10–15%)
• Headache (10–15%)
• Renal impairment (5–10%)

---

Antiplatelet Peptides

Eptifibatide (Integrilin)

Contraindications:

• Active bleeding
• Recent stroke (within 30 days)
• Major surgery (within 6 weeks)
• Platelet count <100,000
• CrCl <50 (dose adjustment required)

Warnings:

• Bleeding (major 1–2%)
• Thrombocytopenia (0.5–1%)

Common adverse effects:

• Bleeding (varies by procedure)
• Nausea (5%)
• Headache (5%)

Tirofiban (Aggrastat)

Contraindications: Same as eptifibatide

Warnings: Same as eptifibatide

Common adverse effects:

• Bleeding (varies)
• Nausea (5%)
• Dizziness (5%)

---

Risk Management

General Monitoring Framework

Baseline	On-Treatment	Periodic
Medical history	Adverse effect monitoring	Safety labs
Physical examination	Efficacy assessment	Imaging (as needed)
Safety labs	Injection site evaluation	Long-term follow-up
Vital signs	Symptom assessment

Emergency Protocols

Emergency	Immediate Action
Anaphylaxis	Epinephrine, airway management, IV access
Severe hypoglycemia	IV dextrose (D50W), glucagon
Severe hyponatremia	Hypertonic saline (3% NaCl)
Acute pancreatitis	NPO, IV fluids, pain management
Severe GI event	Imaging, surgical consultation

References

• Peptide Safety Data
• Peptide Drug Interactions Database
• Peptide Clinical Dosing
• Peptide Storage Conditions
• Peptide Reconstitution Guide